Avera Cancer Sequencing and Analytics Protocol (ASAP)
Recruiting now
Conditions studied: Cancer, Cancer Diagnosis, Early Detection of Cancer, Breast Cancer, Lung Cancer, Colon Cancer, GI Cancer, Gynecologic Cancer, Ovarian Cancer, Endometrial Cancer, CNS Cancer, Hematologic Cancer
In brief
The purpose of this study is to characterize the breadth of molecular features present in participants receiving care within a large, integrated, community-based healthcare system. Through comprehensive genomic profiling, investigators aim to identify the underlying genomic drivers of premalignant and malignant conditions across a range of disease stages and cancer types. Comprehensive molecular profiling will include somatic tumor testing (tissue and/or blood) using next-generation sequencing. Selected subsets of samples may undergo whole exome and/or whole transcriptome sequencing for research purposes. Pharmacogenomic testing will also be performed to better understand individual variability in medication response and to identify opportunities for optimizing treatment. In addition, participants may optionally provide microbiome samples. To maximize the value of the genomic data, participants who consent to this protocol will have their electronic health records-both retrospective and prospective-abstracted, curated, annotated, and linked to the genomic data generated through study testing. Given the long-term value of these data, participants may also voluntarily consent to the storage of their biological samples in a biobank and to the use of their de-identified information for future research. Data collected from this participant population will support efforts to advance the understanding of cancer biology, as well as the discovery and validation of biomarkers associated with clinical outcomes. Findings may also be shared through collaborative research initiatives to further promote advancements in cancer research.
Key facts
- Study ID
- NCT05142033
- Run by
- Avera McKennan Hospital & University Health Center
- People needed
- 25000
- Starts
- 2021-11-01
- Expected to finish
- 2026-12-31
- Last updated by the study team
- 2026-03-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Must be at least 18 years of age
- Must be undergoing a workup or being followed for a premalignant condition or have a diagnosis of cancer
- Must voluntarily sign and understand the most current IRB-approved consent form prior to study participation
You may not qualify if…
- Participants incapable of understanding the items listed in the consent form and process
- Participants with a history of or known psychiatric illness deemed unable to consent or adhere to study requirements
Where it is running
- Avera Cancer Institute - Marshall — Marshall, Minnesota, United States (enrolling)
- Avera Cancer Institute - Aberdeen — Aberdeen, South Dakota, United States (enrolling)
- Avera Cancer Institute - Mitchell — Mitchell, South Dakota, United States (enrolling)
- Avera Cancer Institute - Pierre — Pierre, South Dakota, United States (enrolling)
- Avera Cancer Institute — Sioux Falls, South Dakota, United States (enrolling)
- Avera Cancer Institute - Yankton — Yankton, South Dakota, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.